McKesson Corporation is undervalued despite strong revenue growth, margin expansion, and capital returns; I rate it Buy with a $920 target (13.5% upside). MCK’s strategy focuses on boosting margins by ...

The S&P healthcare index (XLV) saw moderate gains in 2025, reaching a YTD increase of 12.2% by mid-December, though it fell short of its May highs. The sector is the sixth-highest performing sector ...

The global medical image management market is projected to grow at a rate of 7-8% by 2027. This growth is primarily driven by the increasing volume of imaging procedures, rapid advancements in ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

McKesson Corp. engages in providing healthcare services. It operates through the following segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and ...